Drug intelligence / Profile preview

JLP-1310

Development stage: Phase 1
Lead developer: Zai Lab
Administration: Oral

Overview

JLP-1310 is an investigational drug evaluated in clinical trials for its pharmacokinetic properties. It has been studied in a randomized, open-label, single-dose, crossover study to investigate the effect of food on its pharmacokinetics in healthy male volunteers[3][2]. The specific mechanism of action, molecular target(s), and therapeutic indication for JLP-1310 are not detailed in the available sources. There is no evidence that it is a marketed pharmaceutical or that it has advanced beyond early-phase clinical studies.

Beyond the preview

Go deeper on JLP-1310.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JLP-1310.

Explore the full profile